OncoLize

About OncoLize

OncoLize (NL) develops intra-tumoral drug depots to "Treat Tumors from the Inside". This means clinicians can inject and keep certain drugs where they are most effective: inside the tumor mass.

Our patent protected ChemoGell(TM) platform is based on hydrogel technology, an awesome injectable drug depot platform developed at RCSI, Dublin by prof.dr. Helena Kelly and her team. We have an exclusive, world wide license for oncology. The base-patents have recently been granted in US, EU, China and Japan, with more in the pipeline.

With the Gastro-Oncology team at Leiden University Medical Center we recently showed spectacular results in treating pancreatic tumors (PDAC) in KPC3 and PDX mice models: 100% survival as opposed to 0% survival without our product, and no adverse side effects.

Grants recently rewarded by the Dutch Cancer Foundation will cover gastric cancer and ovarian cancers among other indications, delivering Chemo and Immune-modulating compounds and peptides.

ChemoGell (TM) is easily scaled-up at low cost by CMO's and hospital pharmacies alike, and is based on raw materials which are well regulated excipients in Pharma and Med-Tech permanent implants. The platform can load

Keywords

• Biomedical Polymers
• Brain Tumors
• Drug Delivery
• Drug Formulations
• Glioblastoma Multiforma
• Injectable Drug Depots
• Oncology
• Pancreas Tumors
• Pharmaceutical Hydrogels

Address

• Headquarters

  Onder de Kerk 336227BG MaastrichtLimburg, Netherlands

Team by function

Based on 4 public job profiles as of 3 September 2026.

• Executive / C-Suite2
• Research / R&D2